Constipation therapeutic - Nordic Life Science PipelineAlternative Names: Transilon
Latest Information Update: 05 Aug 2016
At a glance
- Originator Nordic life science pipeline
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity No
Highest Development Phases
- Preclinical Constipation
Most Recent Events
- 05 Aug 2016 Preclinical development is ongoing in Canada
- 30 May 2014 Preclinical trials in Constipation in Canada (unspecified route)